Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | ACP1 | P24666 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.64 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.64 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SGPL1 | O95470 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43880 | 1.00 | ESR1 (0.64) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Ammonia Solution, Strong SCHEMBL31241292 | 0.99 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Water SCHEMBL371432 | 0.99 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Hydrochloric Acid SCHEMBL14331173 | 0.99 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL6534833 | 0.89 | HPGD (0.55) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL140749 | 0.88 | HPGD (0.61) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL13176882 | 0.88 | ESR1 (0.64) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL22857703 | 0.87 | HPGD (0.56) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| Pyridoxamine Phosphate Anhydrous SCHEMBL43832 | 0.87 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 | |
| SCHEMBL16420385 | 0.87 | ESR1 (0.63) | ESR1PTGS1ACP1PDE4AP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117646044-A | Method for synthesizing (1R, 2R) -4-methylsulfonyl benzene silk amino alcohol by multi-enzyme cascade and application thereof | 福州大学 | 2024-03-05 | — | — | CN | claimed |
| CN-116098901-A | Compound for treating brain injury | 复旦大学 | 2023-05-12 | — | — | CN | claimed |
| CN-116035050-A | Instant nutrition-balanced nutrition-enriched compressed biscuits and preparation method thereof | 匹克国际贸易(天津)有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| WO-2023031860-A1 | COMPOSITIONS, KITS, AND METHODS TO PROVIDE SYNERGISTIC AND/OR ADDITIVE EFFECTS FROM COMPRISED INGREDIENTS FOR THE PREVENTION, TREATMENT AND MANAGEMENT OF NAUSEA AND VOMITING. | PATEL, Natvarlal Hargovinddas (IN) | 2023-03-09 | — | — | WO | claimed |
| WO-2023031779-A1 | COMPOSITIONS, KITS, AND METHODS TO PROVIDE SYNERGISTIC AND/OR ADDITIVE EFFECTS FROM COMPRISED INGREDIENTS FOR THE PREVENTION, TREATMENT AND MANAGEMENT OF NAUSEA AND VOMITING | PATEL, Natvarlal Hargovinddas (IN) | 2023-03-09 | — | — | WO | claimed |
| CN-122036797-A | Method for efficiently preparing high-purity pyridoxal phosphate by continuous flow | 台州职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| CN-116406269-B | Compositions containing nicotinamide and vitamin B6 and methods of using such compositions for rehabilitation | 雀巢产品有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735008-A1 | IBOGAINE TREATMENT | Ambio Life Sciences Inc. (CA) | 2026-05-06 | — | — | EP | disclosed |
| US-20260076399-A1 | READY-TO-USE PARENTERAL NUTRITION FORMULATION | BAXTER INT (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4704793-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION FOR PROMOTING HAIR STRENGTH | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2026-03-11 | — | — | EP | disclosed |
| US-12507721-B2 | Ready-to-use parenteral nutrition formulation | BAXTER INTERNATIONAL INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4630568-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN | KRKA, D.D., Novo Mesto (SI) | 2025-10-15 | — | — | EP | disclosed |
| CN-114438051-B | Pyridoxine phosphate synthase PdxJ mutant and application thereof in preparation of vitamin B6 | 中国科学院天津工业生物技术研究所 | 2022-06-17 | — | — | CN | disclosed |
| US-20220160734-A1 | TREATMENT OF FIBROIDS WITH VITAMIN D AND AN AGENT SUCH AS EPIGALLOCATECHIN GALLATE (EGCG) | LO.LI. PHARMA S.R.L. (IT) | 2022-05-26 | — | — | US | disclosed |
| CN-111194912-B | Stable medical liquid enteral nutrition composition and preparation method thereof | 北京市营养源研究所有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3995151-A1 | LIPID COMPOSITION FOR ENCAPSULATING AN ACTIVE SUBSTANCE AND ALLOWING CONTROL OF THE SPEED OF RELEASE OF SAID ACTIVE SUBSTANCE | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2022-05-11 | — | — | EP | disclosed |
| CN-114438051-A | Pyridoxine phosphate synthase PdxJ mutant and application thereof in preparation of vitamin B6 | 中国科学院天津工业生物技术研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-114438051-A | Pyridoxine phosphate synthase PdxJ mutant and application thereof in preparation of vitamin B6 | 中国科学院天津工业生物技术研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-20220040272-A1 | METHOD OF TREATING A MAMMAL, INCLUDING HUMAN, AGAINST CANCER USING METHIONINE AND ASPARAGINE DEPLETION | ERYTECH PHARMA (FR) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076399-A1 | READY-TO-USE PARENTERAL NUTRITION FORMULATION | PROC, MMAB, SLC5A6 | ESR1 3948/4885PTGS1 2696/4885ACP1 2499/4885 |
| US-12507721-B2 | Ready-to-use parenteral nutrition formulation | PROC, SLC5A6, GC | ESR1 4646/4885PTGS1 1750/4885ACP1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.